NCT03416244 2022-09-29
RAMONA
AIO-Studien-gGmbH
Phase 2 Completed
Clinical Trials
3 trialsNCT03409848 2022-05-18
INTEGA
AIO-Studien-gGmbH
Phase 2 Completed
NCT03220009 2018-10-03
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn